Alpha 2.0
Login Register
» Articles » PMID: 26180763

An Observational Study to Assess Back Pain in Patients with Severe Osteoporosis Treated with Teriparatide Versus Antiresorptives: An Indian Subpopulation Analysis

Overview
Journal Indian J Endocrinol Metab
Specialty Endocrinology
Date 2015 Jul 17
PMID 26180763
Citations 1
Authors
Harvinder Chhabra
Rajesh Malhotra
Sunil Marwah
Bharat Dave
Kyoungah See
Simrat Sohal
Sirel Gurbuz
Affiliations
Soon will be listed here.
Abstract

Background: One year, prospective, observational study in an Indian subpopulation to assess back pain in patients with severe osteoporosis treated with teriparatide or antiresorptives in a clinical setting.

Materials And Methods: One hundred and nineteen teriparatide-naοve Indian men and postmenopausal women (mean age 68.0 years) with previous osteoporotic vertebral fracture participated. Patients were assessed at baseline, 6-and 12-months to evaluate relative risk (RR) of new/worsening back pain using the Back Pain Questionnaire. The incidence of back pain and changes in back pain severity were assessed using the visual analog scale (VAS); Health outcomes were assessed using the euroquol-5 dimensions (EQ-5D) questionnaire. All tests were conducted with a two-sided alpha of 0.05.

Results: Of 562 overall patients, 57, 60, and 2 Indian patients received teriparatide, antiresorptive, or teriparatide and antiresorptive, respectively. Baseline disease characteristics were slightly worse for antiresorptive-treated patients, whereas teriparatide-treated patients were older with more comorbidities. At 6-months, the incidence of new/worsening back pain was 5.3% for teriparatide-treated patients versus 4.4% for antiresorptive-treated patients (RR: 1.00, 95% confidence interval: 0.68, 1.48); the incidence of severe back pain was 0% versus 12.5% (P = 0.017); in these treatment groups, respectively. Mean VAS change scores (mean ± standard deviation [SD]) were - 1.9 ± 1.73 versus - 1.4 ± 1.77, and mean EQ-5D change scores were 4.2 ± 27.20 versus 9.9 ± 26.23 at 6-months. At 6 months, more teriparatide-treated patients felt better (89% vs. 61%; P = 0.001) and were at least very satisfied with their treatment (30% vs. 9%; P = 0.011).

Conclusion: Teriparatide-treated Indian patients had similar new/worsening back pain risk and minimal risk of severe back pain compared with antiresorptive-treated patients at 6-months.

Citing Articles

Middle East experience from the Asia And Latin America Fracture Observational Study (ALAFOS): Baseline characteristics of postmenopausal women with osteoporosis using teriparatide.

Elsalmawy A, Al-Ali N, Yaghi Y, Assaggaf H, Maalouf G, Sadat-Ali M J Int Med Res. 2020; 48(8):300060520940855.

PMID: 32762404 PMC: 7557781. DOI: 10.1177/0300060520940855.

References
1.
Songpatanasilp T, Mumtaz M, Chhabra H, Yu M, Sorsaburu S . Back pain in patients with severe osteoporosis on teriparatide or antiresorptives: a prospective observational study in a multiethnic population. Singapore Med J. 2014; 55(9):493-501. PMC: 4293947. DOI: 10.11622/smedj.2014120. View
2.
Harinarayan C, Joshi S . Vitamin D status in India--its implications and remedial measures. J Assoc Physicians India. 2009; 57:40-8. View
3.
Body J, Gaich G, Scheele W, Kulkarni P, Miller P, Peretz A . A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002; 87(10):4528-35. DOI: 10.1210/jc.2002-020334. View
4.
Aggarwal N, Raveendran A, Khandelwal N, Sen R, Thakur J, Dhaliwal L . Prevalence and related risk factors of osteoporosis in peri- and postmenopausal Indian women. J Midlife Health. 2012; 2(2):81-5. PMC: 3296391. DOI: 10.4103/0976-7800.92537. View
5.
Francis R, Aspray T, Hide G, Sutcliffe A, Wilkinson P . Back pain in osteoporotic vertebral fractures. Osteoporos Int. 2007; 19(7):895-903. DOI: 10.1007/s00198-007-0530-x. View